Scholarlink

<p>We thank the correspondents for their thoughtful commentary on our recently published computational framework evaluating immune and fibrotic risk associated with dermal filler materials. We clarify that the proposed model was intentionally designed to generate relative, rank-based risk indices rather than absolute clinical event probabilities, a distinction explicitly acknowledged in the original manuscript. Key limitations, including the absence of real-world outcome validation and the exclusion of procedural and time-dependent clinical variables, were clearly stated and reflect current constraints in available denominator-level and patient-specific data. The framework aims to isolate the contribution of filler physicochemical properties and host genetic susceptibility within a controlled, reproducible environment. We view this work as hypothesis-generating and foundational, providing an evidence-organized structure upon which future clinically calibrated and multimodal models may be built.</p><p><i>Level of Evidence IV</i> This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors &#xa0;<a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Authors’ Response to Comment on “When Genes Meet Gels: Computational Immunogenetics of Dermal Fillers and Stratified Risk of Immune and Fibrotic Reactions Across Compositions and Genotypes”

  • 期刊论文

  • 发表日期：

    2026年3月12日

查看全文
  • Eqram Rahman,
  • William Richard Webb

摘要

We thank the correspondents for their thoughtful commentary on our recently published computational framework evaluating immune and fibrotic risk associated with dermal filler materials. We clarify that the proposed model was intentionally designed to generate relative, rank-based risk indices rather than absolute clinical event probabilities, a distinction explicitly acknowledged in the original manuscript. Key limitations, including the absence of real-world outcome validation and the exclusion of procedural and time-dependent clinical variables, were clearly stated and reflect current constraints in available denominator-level and patient-specific data. The framework aims to isolate the contribution of filler physicochemical properties and host genetic susceptibility within a controlled, reproducible environment. We view this work as hypothesis-generating and foundational, providing an evidence-organized structure upon which future clinically calibrated and multimodal models may be built.

Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors  www.springer.com/00266.